Current research on the treatment of primary sclerosing cholangitis

Ahmad H Ali1,*, Elizabeth J Carey1, Keith D Lindor1,2

1 Division of Gastroenterology and Hepatology, Mayo Clinic, Arizona, USA; 2 Arizona State University, College of Health Solutions, Phoenix, Arizona, USA.

Summary

Primary sclerosing cholangitis (PSC) is a progressive disease of the liver characterized by inflammation and destruction of the intra- and/or extra-hepatic bile ducts, leading to fibrosis and ultimately liver failure, cirrhosis and an increased risk of malignancy. The etiology of PSC is unclear. It is often associated with the inflammatory bowel diseases (IBD), particularly Ulcerative Colitis (UC); up to 75% of PSC patients have UC. PSC is more prevalent in men than in women. Ursodeoxycholic acid (UDCA) has been extensively studied in PSC in randomized clinical trials but failed to show a positive impact on the natural course of the disease. Currently, there is no effective medical therapy for PSC, and the majority of patients will eventually require liver transplantation. PSC is one of the leading indications for liver transplantation. In this paper, we review the current research on the potential therapeutic agents for the treatment of PSC.

Keywords: Primary sclerosing cholangitis, ursodeoxycholic acid, obeticholic acid, vancomycin

1. Introduction

Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by ongoing destruction of the intra- and extra-hepatic bile ducts leading to cholestasis, advanced fibrosis, liver cirrhosis and eventually liver failure with its consequent complications such as portal hypertension and an increased risk of malignancy (1-3). PSC affects nearly 50,000 patients in the United States (4). The median life expectancy after diagnosis of PSC is 12 to 18 years without liver transplantation (3,5). PSC is often associated with Ulcerative Colitis (UC) (4), an inflammatory bowel disease (IBD) characterized by chronic ulceration of the large intestine. PSC can occur in association with autoimmune diseases such as autoimmune hepatitis and autoimmune pancreatitis; commonly referred to as the PSC overlap syndromes (6). The diagnosis of PSC is made in patients with a chronic cholestatic biochemical profile when cholangiography shows stricturing of the intra- and/or extra-hepatic bile ducts (7). Small-duct PSC is a variant of PSC characterized by chronic cholestasis, normal cholangiography, and histological findings consistent with PSC (8,9).

Currently, there is no effective medical therapy for PSC. Ursodexoycholic acid (UDCA) is the single most extensively studied agent in PSC. Several controlled and uncontrolled clinical trials have shown significant improvement in liver biochemistries when PSC patients were treated with UDCA (10-15). However, large randomized and controlled prospective clinical trials have failed to demonstrate that UDCA can positively affect the clinical outcomes of patients with PSC (13,15). In fact, the safety of long term use of high-dose UDCA in PSC patients has been questioned, as it has been associated with increased rates of serious adverse events (13,16) and, more recently, with the development of colon cancer (16,17). The American Association for the Study of Liver Disease (AASLD) recommends against the use of UDCA in PSC patients (7). Liver transplantation remains the treatment of choice for end-stage PSC, being the fifth leading indication for liver transplantation in the United States (18). In some Scandinavian countries, PSC is the leading indication for liver transplantation (18-20). Recurrent PSC is an important problem, occurring in the transplanted liver in 20%-40% of PSC patients (18).

Several potential therapeutic avenues in PSC have
been explored over the last 2 decades, some of which have shown promising results. In this paper, we review the current research on the treatment strategies in PSC.

2. Bile acid mimetics and PSC

Twenty-four norUDCA is the C23 homolog of UDCA that is currently being evaluated in a phase II randomized clinical trial in patients with PSC (ClinicalTrials.gov Identifier: NCT01755507). In a rodent model of cholestasis, the administration of norUDCA to Mdr2 knockout mice improved sclerosing cholangitis, possibly by altering the composition of the bile acid pool through displacing the toxic bile acids and increasing the hydrophilicity of the bile acids (21). In a more recent animal model of cholestasis, norUDCA significantly improved indices of liver injury in common bile duct-ligated (CBDL) mice when compared to UDCA (22). Taken together, these results suggest that norUDCA could be of potential benefit in patients with PSC.

3. Farnesoid X receptor agonists and PSC

The farnesoid X receptors (FXRs) are a group of nuclear hormone receptors expressed in high amounts in tissues involved in bile acid metabolism such as liver, intestine, and kidney (23). Recently, bile acids have been identified as natural ligands of FXRs (24,25). FXRs play a key role in bile acid homeostasis by regulation of genes involved in bile acid synthesis, secretion, conjugation, transportation, absorption, and detoxification (26-30). An important target of the FXRs is the gene encoding for cholesterol 7α hydroxylase (CYP7A1) the rate-limiting enzyme in bile acid biosynthesis. When bound to bile acids, FXRs repress the gene encoding for CYP7A1 (24). Moreover, the expression of an important transport protein (cytosolic intestinal bile acid-binding protein) (31) located in the intestines is increased as a result of activation of the FXR (24,32). This protein is believed to play a key role in the regulation of the enterohepatic circulation (24,32). In addition to their role in bile acid homeostasis, FXRs have been found to regulate liver regeneration during liver injury (33-38).

Obeticholic acid (OCA, INT-747), a 6-ethyl derivative of the natural human bile acid chenodeoxycholic acid (CDCA), is a first-in-class selective FXR agonist with ~ 100-fold greater FXR agonistic activity than CDCA (39-41). In a male Wistar rat model of cholestasis, OCA protected hepatocytes against deleterious effects caused by administration of lithocholic acid (LCA) (41). In another animal model, the administration of OCA reduced liver fibrosis and indices of hepatic damage in bile duct ligated rats (42). Collectively, these results suggest that FXR agonists could be of therapeutic benefit in patients with cholestatic liver diseases.

The safety and efficacy of OCA has been evaluated in 2 randomized clinical trials in patients with primary biliary cirrhosis (PBC) with promising results (43,44). The administration of OCA to PBC patients led to a significant reduction of serum alkaline phosphatase (ALP), an important surrogate marker in PBC (43,44). One important adverse event was pruritus, occurring in a dose-dependent manner and leading to discontinuation of the drug in 38% of PBC patients (43,44). Currently, a phase II clinical trial of OCA in PSC patients is ongoing, using lower doses to help avoid pruritus (ClinicalTrials.gov Identifier: NCT02177136).

4. Apical sodium-dependent bile acid transporter inhibitors and PSC

Abnormal bile acid pool composition is thought to play a key role in the pathogenesis and progression of PSC (45). This hypothesis is derived from several animal and human studies. PSC-like lesions occur in mice devoid of the canalicular transporter Mdr2, which mediates biliary excretion of phospholipids that normally form mixed micelles with the bile acids, thus protecting the liver against the detergent effects of bile acids (46). Bile acid toxicity towards the biliary epithelium could result from decreased biliary HCO3 secretion (47). The bile salt-sensing receptor TGR5 plays a key role in the regulation of HCO3 secretion, and interestingly, TGR5 has been identified as a likely disease gene in a large genome-wide study of PSC (48). In Lindor’s high-dose UDCA study in PSC, treatment with high-dose UDCA was associated with an increased rate of serious clinical events when compared with placebo (13). Sinakos et al. investigated the serum bile acid composition in patients in the high-dose UDCA arm and compared that with serum bile acids in patients in the control group (49). They found a significant expansion of the total serum bile acid pool and increased UDCA and LCA enrichment in the UDCA-treated patients versus the placebo group when compared to pretreatment levels (49). In addition, they found that the increase in total serum bile acid pool correlated with worse outcomes in patients with PSC (49). Together, these observations suggest that changes in the bile acid pool could be deleterious in patients with PSC, and alteration of the bile acid pool may be of therapeutic benefit in PSC.

The apical sodium-dependent bile acid transporter (ASBT), also known as the ileal bile acid transporter, is expressed predominantly in the distal ileal tissue and plays a key role in the reabsorption of bile acids from the lumen of the small intestine, which is critical for the enterohepatic circulation of the bile acids (50). Normally, ~ 95% of the secreted bile acids are reabsorbed from the intestine into the portal circulation and back to the liver (51). With this biological rationale, interrupting the enterohepatic circulation could result in a decrease bile acid load on the liver, which in turn could be of potential therapeutic benefit in patients with
PSC. Currently a phase II clinical study evaluating the safety and efficacy of LUM001, an ASBT inhibitor, in patients with PSC is ongoing (ClinicalTrials.gov Identifier: NCT02061540).

5. Antimicrobials and PSC

Several animal experiments demonstrated a link between the gut microbiota and development of PSC (52-59). Induction of small bowel bacterial overgrowth by ligating the jejunum in rats resulted in development of hepatic lesions compatible with PSC (53,55,56). Daily treatment with antibiotics led to significant improvement in these lesions (55), suggesting that gut microbiota modification could be of therapeutic benefit in a selected group of PSC patients.

Vancomycin, metronidazole and minocycline have been evaluated in clinical trials in patients with PSC (60,61). The use of these antibiotics led to a significant reduction in serum ALP, an important surrogate marker in PSC (60,61). Thus antibiotic therapy in PSC patients seems to be a promising tool in the treatment of PSC. However, larger studies are needed to clarify these results.

6. Monoclonal antibodies and PSC

Mucosal adressin cell adhesion molecule 1 (MAdCAM-1), an endothelial cell adhesion molecule, is expressed in high amounts in the gut of patients with IBD and those with IBD and PSC (62-65). Vascular adhesion protein 1 (VAP-1) has been found to induce the expression of MAdCAM-1 in the hepatic endothelial cells of human liver tissue (66). This, in turn, was associated with increased adhesion of lymphocytes from patients with PSC (66). Thus, targeting the VAP-1/MAdCAM-1 could be of beneficial effect in patients with PSC. Vedolizumab is a monoclonal antibody against α4/β7, which is a cell surface glycoprotein expressed on B and T cells and interacts with MAdCAM-1, has shown a beneficial effect in UC (67). This agent could also be of therapeutic benefit in patients with PSC. The VAP-1-blocking agent, BTT1023, is currently being investigated in a phase II clinical trial in patients with PSC (ClinicalTrials.gov Identifier: NCT02239211).

It has been previously shown that the liver-infiltrating lymphocytes in PSC include mucosal T cells recruited to the liver by aberrant expression of the gut-specific chemokine CCL25 that activates α4/β7 binding to MAdCAM-1 on the hepatic endothelium (63,68). Therefore, targeting the CCL25-MAdCAM-1 axis could be of therapeutic benefit in PSC. CCX282-B, a CCR9 antagonist that inhibits CCR9- and CCL25-dependent chemotaxis, has shown efficacy in Crohn’s disease (69). This agent deserves to be investigated in patients with PSC. Lysyl oxidase-like protein 2 (LOXL2) belongs to the lysyl oxidase family and has been shown to contribute to progressive liver damage in experimental models (70). Simtuzumab, a monoclonal antibody against LOXL2, is currently being investigated in a phase II clinical trial in patients with PSC (ClinicalTrials.gov Identifier: NCT01672853).

7. Special cases

Primary sclerosing cholangitis-Autoimmune hepatitis (PSC-AIH) overlap syndrome is a disorder characterized by clinical, biochemical and histological features of AIH in the presence of cholangiographic findings consistent with PSC (71,72). Data on PSC-AIH overlap patients are scarce and long-term outcome is not well-defined. Because of these reasons, there is no consensus on the treatment of patients with PSC-AIH. Recently, Zenouzi et al. (73) reported the long-term follow up on three cases originally described in 1996. All three patients were alive (22, 27, and 25 years after initial presentation) and have shown disease progression, two of whom are on the liver transplantation list (both developed esophageal varices and one developed weight loss). The third patient underwent liver transplantation 22 years after initial presentation. All three patients were on UDCA and immunosuppression therapy (azathioprine) (73). These data suggest that PSC-AIH may have a better prognosis than the classic PSC, and that the combination of UDCA and immunosuppression in PSC-AIH may be of therapeutic benefit and warrants investigation. Given the rarity of PSC-AIH, randomized clinical trials are unlikely to occur.

Autoimmune pancreatitis (AIP) is a chronic pancreatic condition characterized by narrowing of the pancreatic duct, raised immunoglobulin G4 (IgG4) levels, lymphocytic infiltration on biopsy, and response to steroids (74). AIP in association with intra-hepatic and/or extra-hepatic bile duct structuring similar to those present in PSC is termed autoimmune pancreatitis-sclerosing cholangitis (AIP-SC) (7). It is unclear whether PSC and AIH represent different ends of the same disease or are separate clinical conditions. Patients with AIP-SC seem to respond to corticosteroids (75). However, studies are needed to clarify the long-term effects of corticosteroid therapy in patients with AIP-SC which are unlikely to occur given the rarity of the disease.

8. Conclusion

PSC is progressive disease of the liver that ultimately leads to cirrhosis and liver failure. There is no effective medical therapy for PSC. Recent advances in understanding the pathological mechanisms that contribute to the hepatobiliary damage in PSC have
led to the development of clinical programs to evaluate potential candidates as therapeutic tools in PSC. Several early-phase clinical trials evaluating these agents are underway.

References

26. Cariou B, Staels B. FXR: A promising target for the


(Received October 11, 2014; Revised November 10, 2014; Accepted November 11, 2014)